MedTrace Logo

Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial

NCT04383717 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-13

No results posted yet for this study

Summary

The use of both levamisole \& Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection

Conditions

  • Respiratory Tract Infections

Interventions

DRUG

Levamisole and isoprinosine

oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks

DRUG

Azithromycin and hydroxychloroquine

oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mohamed El Darouti, Professor · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-05
Primary Completion
2020-08-30
Completion
2020-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04383717 on ClinicalTrials.gov